Amgen Inc. (AMGN)
After hours:
| Previous Close | 228.90 |
| Open | 230.60 |
| Bid | 224.00 x 1300 |
| Ask | 231.69 x 1000 |
| Day's Range | 227.36 - 231.37 |
| 52 Week Range | 198.64 - 276.69 |
| Volume | |
| Avg. Volume | 2,835,845 |
| Market Cap | 128.267B |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | 23.47 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 7.76 (3.32%) |
| Ex-Dividend Date | Feb. 14, 2022 |
| 1y Target Est | N/A |
- Business Wire
Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement
THOUSAND OAKS, Calif. & CAMBRIDGE, Mass., January 06, 2022--AMGEN & GENERATE BIOMEDICINES ANNOUNCE MULTI-TARGET, MULTI-MODALITY RESEARCH COLLABORATION AGREEMENT
- GlobeNewswire
BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors
NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams f
- CNW Group
deCODE genetics: Predicting the probability of death
Scientists from deCODE genetics have developed a predictor based on protein measurements in blood samples that predicts the time to all-cause death better than traditional risk factors.
